Literature DB >> 24712482

Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes.

Amer M Zeidan1, Ju-Whei Lee, Thomas Prebet, Peter Greenberg, Zhuoxin Sun, Mark Juckett, Mitchell R Smith, Elisabeth Paietta, Janice Gabrilove, Harry P Erba, Martin S Tallman, Steven D Gore.   

Abstract

The revised International Prognostic Scoring System (IPSS-R) was developed in a cohort of untreated myelodysplastic syndromes (MDS) patients. A French Prognostic Scoring System (FPSS) was recently reported to identify differential survival among azacitidine-treated patients with high-risk MDS. We applied the FPSS and IPSS-R to 150 patients previously randomized to azacitidine monotherapy or a combination of azacitidine with entinostat (a histone deacetylase inhibitor). Neither score predicted response but both discriminated patients with different overall survival (OS; median OS, FPSS: 9·7, 14·7, and 25·3 months, P = 0·018; IPSS-R: 12·5, 11·3, 20·8, and 36 months, P = 0·005). Statistical analysis suggested no improvement in OS prediction for the FPSS over the IPSS-R in azacitidine-treated patients.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  French Prognostic Scoring System; azacitidine; myelodysplastic syndromes; prognostic models; revised International Prognostic Scoring System

Mesh：

Substances：

Year:  2014        PMID： 24712482      PMCID： PMC4299460          DOI： 10.1111/bjh.12884

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


  22 in total

1.  Myelodysplastic syndromes standardized response criteria: further definition.

Authors:  B D Cheson; J M Bennett; H Kantarjian; C A Schiffer; S D Nimer; B Löwenberg; R M Stone; M Mittelman; G F Sanz; P W Wijermans; P L Greenberg
Journal:  Blood       Date:  2001-09-15       Impact factor: 22.113

2.  Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response.

Authors:  Massimo Breccia; Giuseppina Loglisci; Laura Cannella; Paola Finsinger; Marco Mancini; Alessandra Serrao; Michelina Santopietro; Adriano Salaroli; Giuliana Alimena
Journal:  Leuk Lymphoma       Date:  2012-01-11

3.  Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

Authors:  R Itzykson; O Kosmider; T Cluzeau; V Mansat-De Mas; F Dreyfus; O Beyne-Rauzy; B Quesnel; N Vey; V Gelsi-Boyer; S Raynaud; C Preudhomme; L Adès; P Fenaux; M Fontenay
Journal:  Leukemia       Date:  2011-04-15       Impact factor: 11.528

4.  Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.

Authors:  Lieke H van der Helm; Canan Alhan; Pierre W Wijermans; Marinus van Marwijk Kooy; Ron Schaafsma; Bart J Biemond; Aart Beeker; Mels Hoogendoorn; Bastiaan P van Rees; Okke de Weerdt; Jurgen Wegman; Ward J Libourel; Sylvia A Luykx-de Bakker; Monique C Minnema; Rolf E Brouwer; Fransien Croon-de Boer; Matthijs Eefting; Kon-Siong G Jie; Arjan A van de Loosdrecht; Jan Koedam; Nic J G M Veeger; Edo Vellenga; Gerwin Huls
Journal:  Br J Haematol       Date:  2011-10-08       Impact factor: 6.998

5.  International scoring system for evaluating prognosis in myelodysplastic syndromes.

Authors:  P Greenberg; C Cox; M M LeBeau; P Fenaux; P Morel; G Sanz; M Sanz; T Vallespi; T Hamblin; D Oscier; K Ohyashiki; K Toyama; C Aul; G Mufti; J Bennett
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

6.  Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

Authors:  Lewis R Silverman; David R McKenzie; Bercedis L Peterson; James F Holland; Jay T Backstrom; C L Beach; Richard A Larson
Journal:  J Clin Oncol       Date:  2006-08-20       Impact factor: 44.544

7.  Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

Authors:  Lewis R Silverman; Erin P Demakos; Bercedis L Peterson; Alice B Kornblith; Jimmie C Holland; Rosalie Odchimar-Reissig; Richard M Stone; Douglas Nelson; Bayard L Powell; Carlos M DeCastro; John Ellerton; Richard A Larson; Charles A Schiffer; James F Holland
Journal:  J Clin Oncol       Date:  2002-05-15       Impact factor: 44.544

8.  Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure.

Authors:  Thomas Prébet; Steven D Gore; Benjamin Esterni; Claude Gardin; Raphael Itzykson; Sylvain Thepot; François Dreyfus; Odile Beyne Rauzy; Christian Recher; Lionel Adès; Bruno Quesnel; C L Beach; Pierre Fenaux; Norbert Vey
Journal:  J Clin Oncol       Date:  2011-07-25       Impact factor: 44.544

9.  Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine.

Authors:  Raphael Itzykson; Sylvain Thépot; Bruno Quesnel; Francois Dreyfus; Odile Beyne-Rauzy; Pascal Turlure; Norbert Vey; Christian Recher; Caroline Dartigeas; Laurence Legros; Jacques Delaunay; Célia Salanoubat; Sorin Visanica; Aspasia Stamatoullas; Francoise Isnard; Anne Marfaing-Koka; Stephane de Botton; Youcef Chelghoum; Anne-Laure Taksin; Isabelle Plantier; Shanti Ame; Simone Boehrer; Claude Gardin; C L Beach; Lionel Adès; Pierre Fenaux
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

10.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316
View more
  9 in total

1.  Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides.

Authors:  A M Zeidan; M A Sekeres; G Garcia-Manero; D P Steensma; K Zell; J Barnard; N A Ali; C Zimmerman; G Roboz; A DeZern; A Nazha; E Jabbour; H Kantarjian; S D Gore; J P Maciejewski; A List; R Komrokji
Journal:  Leukemia       Date:  2015-10-14       Impact factor: 11.528

2.  Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents.

Authors:  Amer M Zeidan; Xin Hu; Weiwei Zhu; Maximilian Stahl; Rong Wang; Scott F Huntington; Smith Giri; Jan Philipp Bewersdorf; Nikolai A Podoltsev; Steven D Gore; Xiaomei Ma; Amy J Davidoff
Journal:  Leuk Lymphoma       Date:  2019-10-01

Review 3.  Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?

Authors:  Aziz Nazha; Mikkael A Sekeres; Steven D Gore; Amer M Zeidan
Journal:  Oncologist       Date:  2015-07-20

Review 4.  MDS prognostic scoring systems – past, present, and future.

Authors:  Brian A Jonas; Peter L Greenberg
Journal:  Best Pract Res Clin Haematol       Date:  2014-11-11       Impact factor: 3.020

5.  Platelet count doubling after the first cycle of azacitidine therapy predicts eventual response and survival in patients with myelodysplastic syndromes and oligoblastic acute myeloid leukaemia but does not add to prognostic utility of the revised IPSS.

Authors:  Amer M Zeidan; Ju-Whei Lee; Thomas Prebet; Peter Greenberg; Zhuoxin Sun; Mark Juckett; Mitchell R Smith; Elisabeth Paietta; Janice Gabrilove; Harry P Erba; Rhett P Katterling; Martin S Tallman; Steven D Gore
Journal:  Br J Haematol       Date:  2014-07-04       Impact factor: 6.998

Review 6.  Improving Prognostic Modeling in Myelodysplastic Syndromes.

Authors:  Aziz Nazha; Mikkael A Sekeres
Journal:  Curr Hematol Malig Rep       Date:  2016-12       Impact factor: 3.952

7.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

8.  Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome.

Authors:  Seung-Hyun Jung; Yoo-Jin Kim; Seon-Hee Yim; Hye-Jung Kim; Yong-Rim Kwon; Eun-Hye Hur; Bon-Kwan Goo; Yun-Suk Choi; Sug Hyung Lee; Yeun-Jun Chung; Je-Hwan Lee
Journal:  Oncotarget       Date:  2016-08-23

9.  BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia.

Authors:  Valérie Vidal; Guillaume Robert; Laure Goursaud; Laetitia Durand; Clemence Ginet; Jean Michel Karsenti; Frederic Luciano; Lauris Gastaud; Georges Garnier; Thorsten Braun; Pierre Hirsch; Emmanuel Raffoux; Anne Marie Nloga; Rose Ann Padua; Hervé Dombret; Pierre Rohrlich; Lionel Ades; Christine Chomienne; Patrick Auberger; Pierre Fenaux; Thomas Cluzeau
Journal:  Oncotarget       Date:  2017-07-18
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.